Tag: Product Hopping

By Michael A. Carrier (Rutgers Law School) Brand-name drug companies frequently switch from one version of a drug to another. Sometimes, the switch is made...

This piece discusses pharmaceutical product reformulations and product hopping strategies, along with the impact that antitrust scrutiny may have on innovation incentives. The main...

Posted by Social Science Research Network The Need for Clarification on Product Hopping: Open Questions after Namenda and Doryx By Lindsey M. Edwards (Wilson Sonsini Goodrich...

Posted by Social Science Research Network Biologics: The New Antitrust Frontier By Michael A. Carrier & Carl J. Minniti III (Rutgers University) Abstract:      The pharmaceutical...

Posted by Social Science Research Network Intellectual Property and Competition Law By C. Scott Hemphill (New York University) Abstract:      This chapter, prepared for the Oxford...

In this issue: In the antitrust debate arena, health care topics are the gifts that just keep on giving—always something new to discuss, analyze, or...

This article is part of a Chronicle. See more from this Chronicle Michael Carrier, Nov 24, 2014 The pharmaceutical industry is unique in its complexity. Markets...

This article is part of a Chronicle. See more from this Chronicle George Addy, Erika Douglas, Mar 26, 2014 The Canadian Competition Bureau has been signaling...